SignalSilence® IGF-I Receptor siRNA I

✓ 10 µM in 300 µl (100 transfections)



Orders ■ 877-616-CELL (2355)

orders@cellsignal.com

Support ■ 877-678-TECH (8324)

info@cellsignal.com

Web ■ www.cellsignal.com

rev. 02/16/16

For Research Use Only. Not For Use In Diagnostic Procedures.


Species Cross-Reactivity: H

Description SignalSilence® IGF-I Receptor siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit IGF-I Receptor expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. IGF-I Receptor siRNA I is 100% homologous with IGF-I Receptor α and β mRNA. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis

Background: Type I insulin-like growth factor receptor (IGF-IR) is a transmembrane receptor tyrosine kinase that is widely expressed in many cell lines and cell types within fetal and postnatal tissues (1-3). Receptor autophosphorylation follows binding of the IGF-I and IGF-II ligands. Three tyrosine residues within the kinase domain (Tyr1131, Tyr1135 and Tyr1136) are the earliest major autophosphorylation sites (4). Phosphorylation of these three tyrosine residues is necessary for kinase activation (5,6). Insulin receptors (IRs) share significant structural and functional similarity with IGF-I receptors, including the presence of an equivalent tyrosine cluster (Tyr1146/1150/1151) within the kinase domain activation loop. Tyrosine autophosphorylation of the insulin receptor is one of the earliest cellular responses to insulin stimulation (7). Autophosphorylation begins with phosphorylation of Tyr1146 and either Tyr1150 or Tyr1151, while full kinase activation requires triple tyrosine phosphorylation (8)

Directions for Use: CST recommends transfection with 100 nM IGF-I Receptor siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.



Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® IGF-I Receptor siRNA I (+), using IGF-I Receptor β (111A9) Rabbit mAb #3018 (upper) or α -Tubulin (11H10) Rabbit mAb #2125 (lower). The IGF-I Receptor eta (111A9) Rabbit mAb confirms silencing of IGF-I Receptor etaexpression, while the lpha-Tubulin (11H10) Rabbit mAb is used as a loading control.

Entrez-Gene ID #3480 Swiss-Prot Acc. #P08069

Storage: IGF-I Receptor siRNA I is supplied in RNAse-free water. Aliquot and store at -20°C.

Please visit www.cellsignal.com for a complete listing of recommended companion products.

Background References:

- (1) Adams, T.E. et al. (2000) Cell. Mol. Life Sci. 57, 1050-1093.
- (2) Baserga, R. et al. (2000) Oncogene 19, 5574-5581.
- (3) Scheidegger, K.J. et al. (2000) J. Biol. Chem. 275, 38921-38928.
- (4) Hernandez-Sanchez, C. et al. (1995) J. Biol. Chem. 270, 29176-29181.
- (5) Lopaczynski, W. et al. (2000) Biochem. Biophys. Res. Commun. 279, 955-960.
- (6) Baserga, R. et al. (1999) Exp. Cell Res. 253, 1-6.
- (7) White, M.F. et al. (1985) J. Biol. Chem. 260, 9470-9478.
- (8) White, M.F. et al. (1988) J. Biol. Chem. 263, 2969-2980.